Exelixis’ trial of Cabometyx and Tecentriq for patients with metastatic non-small cell lung cancer failed to meet its goal of extending overall survival compared to chemotherapy.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,